13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001937964
Total reported value
$541.9M
$541.9M
50 檔
76.2%
In Q4 2025, Artia Global Partners LP's U.S. equity holdings reached a combined market value of $541.9M, distributed across 50 disclosed stock positions.
In Q4 2025, Artia Global Partners LP displayed an active expansion posture, initiating 19 new positions and adding to 15 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | Stock-Healthcare | 27.18% | -18.15% | -2.65% | |
| 2 | ABVX | Abivax Sa-adr | Stock-Other | 11.67% | -0.69% | +170.85% | |
| 3 | ARGX | Argenx Se - Adr | Stock-Healthcare | 7.71% | +0.74% | -17.38% | |
| 4 | LLY | Eli Lilly & Co | Stock-Healthcare | 7.69% | -7.04% | EXIT | |
| 5 | UGL | Proshares Ultra Gold | ETF-Commodities | 4.26% | — | +0.88% | |
| 6 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.83% | -0.46% | EXIT | |
| 7 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 3.59% | +0.12% | +392.11% | |
| 8 | TRVI | Trevi Therapeutics Inc | Stock-Other | 3.57% | +2.80% | +0.70% | |
| 9 | QURE | uniQure N.V. | Stock-Other | 3.47% | — | +55.35% | |
| 10 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 2.50% | -0.08% | +158.64% | |
| 11 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 2.48% | — | — | |
| 12 | CDTX | Cidara Therapeutics Inc | Stock-Other | 2.22% | — | — | |
| 13 | EYPT | Eyepoint Inc | Stock-Other | 1.99% | +0.04% | +22.08% | |
| 14 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.62% | -0.06% | +139.92% | |
| 15 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.20% | +0.19% | +88.64% | |
| 16 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.18% | +3.98% | — | |
| 17 | DGX | Quest Diagnostics Inc | Stock-Healthcare | 1.00% | +0.95% | -50.05% | |
| 18 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.98% | — | -49.67% | |
| 19 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.89% | — | — | |
| 20 | PVLA | Palvella Therapeutics Inc | Stock-Other | 0.88% | — | — | |
| 21 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.71% | -0.06% | +143.46% | |
| 22 | SION | Sionna Therapeutics Inc | Stock-Other | 0.70% | +0.01% | — | |
| 23 | PALI | Palisade Bio Inc | Stock-Other | 0.66% | +0.07% | — | |
| 24 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.61% | — | -45.41% | |
| 25 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.60% | +0.03% | — | |
| 26 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.60% | +0.20% | +114.38% | |
| 27 | PROK | Prokidney CORP | Stock-Other | 0.58% | +0.03% | — | |
| 28 | ASND | Ascendis Pharma A/S | Stock-Other | 0.54% | -0.81% | EXIT | |
| 29 | ABBV | Abbvie Inc | Stock-Healthcare | 0.47% | -0.63% | EXIT | |
| 30 | BLTE | Belite Bio Inc - Adr | Stock-Other | 0.41% | -0.09% | — | |
| 31 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.40% | +0.13% | — | |
| 32 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.39% | — | +60.40% | |
| 33 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.38% | +3.13% | +128.80% | |
| 34 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 0.37% | -0.06% | — | |
| 35 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.35% | -0.09% | — | |
| 36 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.28% | +0.04% | — | |
| 37 | UPB | Upstream Bio Inc | Stock-Other | 0.26% | — | — | |
| 38 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.25% | -0.04% | — | |
| 39 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.22% | -0.30% | EXIT | |
| 40 | BTSG | Brightspring Health Services | Stock-Other | 0.22% | +6.20% | — | |
| 41 | PEPG | Pepgen Inc | Stock-Other | 0.19% | — | — | |
| 42 | CELC | Celcuity Inc | Stock-Other | 0.18% | +0.79% | — | |
| 43 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.17% | +0.06% | — | |
| 44 | NUVL | Nuvalent Inc-a | Stock-Other | 0.12% | +0.01% | — | |
| 45 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.11% | -0.09% | EXIT | |
| 46 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.10% | -0.01% | — | |
| 47 | ANRO | Alto Neuroscience Inc | Stock-Other | 0.07% | — | — | |
| 48 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.07% | -0.02% | — | |
| 49 | KOD | Kodiak Sciences Inc | Stock-Other | 0.07% | -0.01% | — | |
| 50 | LYRA | Lyra Therapeutics Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | +8.6% | +170.85% | Add |
| 2 | LLY | Eli Lilly & Co | +4.2% | +75.96% | Add |
| 3 | VKTX | Viking Therapeutics Inc | +3% | +392.11% | Add |
| 4 | NAMS | NewAmsterdam Pharma Company N.V. | +1.6% | +158.64% | Add |
| 5 | INSM | Insmed Inc | +1.3% | -2.65% | Trim |
| 6 | IONS | Ionis Pharmaceuticals Inc | +1% | +139.92% | Add |
| 7 | TRVI | Trevi Therapeutics Inc | +0.7% | +0.70% | Add |
| 8 | EYPT | Eyepoint Inc | +0.6% | +22.08% | Add |
| 9 | DNTH | Dianthus Therapeutics Inc | +0.5% | +88.64% | Add |
| 10 | RVMD | Revolution Medicines Inc | +0.4% | — | Unchanged |
| 11 | MLYS | Mineralys Therapeutics Inc | +0.4% | +143.46% | Add |
| 12 | UGL | Proshares Ultra Gold | +0.3% | +0.88% | Add |
| 13 | RAPP | Rapport Therapeutics Inc | +0.3% | +114.38% | Add |
| 14 | TVTX | Travere Therapeutics Inc | +0.3% | +128.80% | Add |
| 15 | AZNN | Astrazeneca Plc-spons Adr | +0.2% | — | Unchanged |
| 16 | ASND | Ascendis Pharma A/S | +0.2% | +44.93% | Add |
| 17 | OCUL | Ocular Therapeutix Inc | +0.1% | +60.40% | Add |
| 18 | BBIO | Bridgebio Pharma Inc | +0.1% | — | Unchanged |
| 19 | PTGX | Protagonist Therapeutics Inc | 0% | — | Unchanged |
| 20 | SRRK | Scholar Rock Holding CORP | 0% | — | Unchanged |
| 21 | BTSG | Brightspring Health Services | 0% | — | Unchanged |
| 22 | UTHR | United Therapeutics CORP | 0% | — | Unchanged |
| 23 | XENE | Xenon Pharmaceuticals Inc | — | — | Unchanged |
| 24 | KNSA | Kiniksa Pharmaceuticals International, plc | 0% | — | Unchanged |
| 25 | ABBV | Abbvie Inc | -0.1% | — | Unchanged |
| 26 | RNAGBP | Avidity Biosciences Inc | -0.2% | -45.41% | Trim |
| 27 | ARGX | Argenx Se - Adr | -1.5% | -17.38% | Trim |
| 28 | DGX | Quest Diagnostics Inc | -1.5% | -50.05% | Trim |
| 29 | ALNY | Alnylam Pharmaceuticals Inc | -1.5% | -49.67% | Trim |
| 30 | QURE | uniQure N.V. | -2.6% | +55.35% | Add |
| 31 | SLNOEUR | Soleno Therapeutics Inc | -3.4% | -13.16% | Trim |
| 32 | VRNA | Verona Pharma PLC - Adr | — | EXIT | Sold out |
| 33 | ✓ | Merus N V | — | EXIT | Sold out |
| 34 | VRTX | Vertex Pharmaceuticals Inc | — | EXIT | Sold out |
| 35 | BSX | Boston Scientific CORP | — | EXIT | Sold out |
| 36 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 37 | RARE | Ultragenyx Pharmaceutical In | — | EXIT | Sold out |
| 38 | VTYXUSD | Ventyx Biosciences Inc | — | NEW | New buy |
| 39 | PVLA | Palvella Therapeutics Inc | — | NEW | New buy |
| 40 | REGN | Regeneron Pharmaceuticals | — | EXIT | Sold out |
| 41 | SION | Sionna Therapeutics Inc | — | NEW | New buy |
| 42 | PALI | Palisade Bio Inc | — | NEW | New buy |
| 43 | PROK | Prokidney CORP | — | NEW | New buy |
| 44 | NKTR | Nektar Therapeutics | — | EXIT | Sold out |
| 45 | 260 | Centessa Pharmaceuticals-adr | — | EXIT | Sold out |
| 46 | BLTE | Belite Bio Inc - Adr | — | NEW | New buy |
| 47 | ROIV | Roivant Sciences Ltd. | — | NEW | New buy |
| 48 | DRUG | Bright Minds Biosciences Inc | — | NEW | New buy |
| 49 | TGTX | Tg Therapeutics Inc | — | EXIT | Sold out |
| 50 | UPB | Upstream Bio Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Artia Global Partners LP reported a total U.S. public equity portfolio value of $541.9M across 50 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INSM, ABVX, ARGX) accounted for 76.2% of total reported equity market value during Q4 2025.
Top New Position Initiated
CDTX
市值: $15.6M
Top Position Liquidated / Trimmed
VRNA
前期市值: $40.4M
During Q4 2025, Artia Global Partners LP's top holdings by market value included INSM (27.2%)、ABVX (11.7%)、ARGX (7.7%). The largest single position, INSM, represented 27.2% of total portfolio value.
In Q4 2025, Artia Global Partners LP made 57 total portfolio adjustments, initiating 19 new buys, adding to 15 positions, trimming 6 holdings, and fully liquidating 17 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.